Immune Thrombocytopenic Purpura – Unmet Need – Unmet Need – Immune Thrombocytopenic Purpura (US/EU)

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder marked by increased platelet destruction and impaired megakaryocyte production. Bleeding ranges from petechiae to lifethreatening hemorrhage, and severity does not always match platelet count. The ITP treatment landscape is evolving as clinicians continue shifting away from chronic steroid use toward targeted, bettertolerated therapies. TPOreceptor agonists such as Nplate (Amgen), Promacta / Revolade (Novartis), and Doptelet (Sobi) are foundational; however, competition is intensifying as drugs with diverse mechanisms such as the SKY inhibitor Tavalisse / Tavlesse (Rigel / Grifols) and the BTK inhibitor Wayrilz (Sanofi) become available.

Questions answered

• How important are clinical treatment attributes in hematologists’ prescribing decisions?
• How do key current therapies, such as Nplate, Promacta / Revolade, and Doptelet, perform on key clinical drug attributes for ITP? How satisfied are hematologists with current therapies?
• What are the greatest unmet needs and most attractive opportunities in this patient population?
• What trade-offs are surveyed hematologists willing to make across key drug attributes and price when considering a hypothetical target product profile?

Product description

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.

Geography: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 30 European hematologists

Key drugs covered: Nplate, Promacta / Revolade, Doptelet, Tavalisse, Wayrilz

Key analyses: Importance of clinical and nonclinical product attributes to physicians; assessment of current drug performance against treatment drivers and goals; physician perceptions of unmet needs in the indication and related indications; remaining drug development opportunities.

Key feature: Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.